Conditional cardiac overexpression of S100A6 attenuates myocyte hypertrophy and apoptosis following myocardial infarction

Current Pharmaceutical Design

Volumn 20, Issue 12, 2014, Pages 1941-1949

  Tsoporis, James N ^a   Izhar, Shehla ^a   Desjardins, Jean Francois ^a   Leong Poi, Howard ^a   Parker, Thomas G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Calcium binding proteins; Hypertrophy; Myocardial infarction; S100A6; Transgenic

Indexed keywords

CALCYCLIN; CASPASE 3; COMPLEMENTARY DNA; DOXYCYCLINE; MYOSIN HEAVY CHAIN ALPHA; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; CELL CYCLE PROTEIN; PROTEIN S 100; S100A6 PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PRESERVATION; HEART VENTRICLE REMODELING; IN VIVO STUDY; MOUSE; MUSCLE HYPERTROPHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; HUMAN; HYPERTROPHY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; GENE EXPRESSION REGULATION; HUMANS; HYPERTROPHY; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; S100 PROTEINS;

EID: 84898640616     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990444     Document Type: Article

References (29)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990; 81: 1161-1172.
2. Orn S, Aukrust P. The prediction of adverse cardiac remodeling following myocardial infarction: defining the need for a dynamic multimarker approach. Heart 2012; 98: 1112-1113.
3. Yang F, Liu YH, Yang XP, Kapke A, Carretero O. Myocardial infarction and cardiac remodeling in mice. Experim Physiol 2002; 87: 547-555.
4. Parker TG. Molecular biology of cardiac growth and hypertrophy. Herz 1993; 18: 245 255.
5. Tsoporis JN, Marks A, Haddad A, O'Hanlon D, Jolly S, Parker TG. S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes. Exp Cell Res 2005; 303: 471-481.
6. Donato R, Cannon BR, Sorci G, et al. Functions of S100 Proteins. Curr Mol Med 2012; 12: 1-34.
7. Lesniak W, Slomnicki LP, Filipek A. S100A6-New facts and fea-tures. Biochem Biophys Res Commun 2009; 390: 1087-1092.
8. Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 2007; 282: 31317-31331.
9. Tsoporis JN, Izhar S, Parker TG. Expression of S100A6 in cardiac myocytes limits apoptosis induced by tumor necrosis factor-a. J Biol Chem 2008; 283: 30174-30183.
10. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest. 2002; 109: 735-743.
11. Yang LL, Gros R, Golam KM, et al. Conditional cardiac overex pression of endothelin-1 induces inflammation and dilated cardio myopathy in mice. Circulation 2004; 109: 255-261.
12. Desjardins JF, Pourdjabbar A, Quan A, et al. Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H1457-H1465.
13. Connelly KA, Kelly DJ, Zhang Y, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007; 76: 280-291.
14. Tsoporis JN, Marks A, Kahn HJ, et al. S100beta inhibits alpha1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. J Biol Chem 1997; 272: 31915-31921.
15. Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010; 106: 93-101.
16. Akasaka Y, Morimoto AY, Ishikawa Y, et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod Pathol 2006; 19: 588-598.
17. Abbate A, Narula J. Role of apoptosis in adverse ventricular remodeling Heart Fail Clin 2012; 8: 79-86.
18. Leong S, Christopherson RJ, Baxter RC. Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem 2007; 20: 579-590.
19. Silomnicki LP, Nawrot B, Leisniak W. S100A6 binds p53 and affects its activity. Int J Biochem Cell Biol 2009; 41: 784-790.
20. Joo JH, Yoon SY, Kim JH, et al. S100A6 (calcyclin) enhances the sensitivity to apoptosis via the upregulation of caspase-3 activity in Hep38 cells. J Cell Biochem 2008; 103: 1183-1197.
21. Fernandez-Fernandez MR, Rutherford TJ, Fersht AR. Members of the S100 family bind p53 in two distinct ways. Protein Sci 2008; 17: 1663-1670.
22. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: Functions and pathology. Trends Biochem Sci 1996; 21: 134-140.
23. 2+-binding protein S100A1 in chronic pulmonary hypertension. Biochim Biophys Acta 2000; 1500: 249-255.
24. Remppis A, Greten T, Schafer BW, et al. Altered expression of the ++ Ca -binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996; 1313: 2 53-57.
25. Most P, Bernotat J, Ehlermann P, et al. S100A1: A regulator of myocardial contractility. Proc Natl Acad Sci USA 2001; 98: 13889-13894.
26. Du XJ, Cole TJ, Tenis N, et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol 2002; 22: 2821-2829.
27. Most P, Boerries M, Eicher C, et al. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase Vi (ERK1/2). J Biol Chem 2003; 278: 48404-48412.
28. Tsoporis JN, Marks A, Kahn HJ, et al. Inhibition of norepineph-rine-induced cardiac hypertrophy in S100B transgenic mice. J Clin Invest 1998; 102: 1609-1616.
29. Tsoporis JN, Marks A, Haddad, A, Dawood F, Liu PP, Parker TG. S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circ 2005; 111: 598-606.